ARTICLE | Clinical News

Soluble complement receptor 1: TCEL and SmithKline Beecham agreed to close the initial Phase I trial of sCR1 conducted by SmithKline in burn patients at risk of

April 4, 1994 7:00 AM UTC

The trial will be unblinded and data analyzed and used to provide initial safety and pharmacokinetic data in support of new clinical trials.

TCEL plans to initiate trials in a larger population of ARDS patients as well as broaden clinical evaluation of the product into a cardiovascular indication. Both of these trials will use sCR1 produced from a new manufacturing process developed by SmithKline. ...